Major investment to evaluate whether blood can be used as a sample to diagnose pediatric lower respiratory tract infections, which are linked to 700,000 child deaths each year.

High-impact antimicrobial resistance innovations programme chooses Dragonfly to be adapted as a new, rapid test for the effective management of urinary tract infections (UTIs).

Pivotal breakthrough achieved through validation of its ability to detect the asymptomatic malaria carriers that sustain transmission, solving the biggest challenge in elimination efforts.

The Dragonfly diagnostics platform wins the prestigious award for its rapid, on-site pathogen detection, enabling swine producers to proactively manage swine herd health, cut antibiotic use, and optimise their supply chains.

ProtonDx’s IMPACT-Farm Alliance partnership secures Large R&D Partnership grant from Innovate UK to develop Lacewing to help tackle antimicrobial resistance (AMR) and pig disease.

ProtonDx’s Dragonfly diagnostic platform excels in Zambia, further proving its resilience, flexibility and portability and making it ideal for healthcare testing in any environment.

Investment will accelerate the development of Lacewing to tackle the global antimicrobial resistance (AMR) crisis.

ProtonDx will be an exhibitor at London’s Festival of Genomics & Biodata, the UK’s largest life sciences event, in London this month.

As 2024 comes to an end, we reflect on a year marked by innovation in diagnostics and sample preparation and positive engagement with the world’s dynamic infectious disease community.

Infectious disease specialist and adventurer Major Scott Pallett pitched his tent 600 km north of the Arctic Circle armed with Dragonfly to put the portable, rapid, multi-pathogen, molecular diagnostic platform to the test.

ProtonDx’s Regulatory Affairs Director, Dr Kasia Szostak-Lipowicz, was invited to the UN Panel on Transformative Digital Diagnostic Technologies, where she discussed how ProtonDx’s work can help bridge healthcare gaps in Africa.

The POCT-for-Scot evaluation emphasises critical aspects of ProtonDx's diagnostic device that are key for point-of-care settings such as accuracy, portability, user-friendliness, patient comfort, and ease of adoption.

Dr Rodriguez Manzano's promotion to Associate Professor in the Department of Infectious Disease at Imperial College London showcases his dedication to advancing the field of molecular diagnostics, with a particular focus on addressing infections and antimicrobial resistance (AMR).

The Tour de France demands quick decisions and immediate health assessments, and this is where Dragonfly, with its rapid testing capabilities, came to the rescue.

ProtonDx's proprietary rapid multipathogen test was a key diagnostic element used to test the Finnish cross-country skiers in the FIS Nordic World Ski Championships in Planica, Slovenia, in February and March 2023.

Ann Wong brings extensive experience of scaling organisations and leading finance operations.

Rapid molecular point-of-care diagnostic system reliably detects SARS-CoV-2, Flu A, Flu B, RSV and Human Rhinovirus. Clinical test results for CTDA validation achieved 100% sensitivity and 100% specificity. UK approval follows CE-IVD mark.

Exclusive rights to distribute CE-IVD marked Dragonfly diagnostic system in key client segments. Dragonfly system able to detect five common respiratory pathogens at once.

Assistant Professor Jesus Rodriguez Manzano, Co-Founder and CSO at ProtonDx, and Deputy Director of the Centre for Antimicrobial Optimisation (CAMO) at Imperial College, shares his views on the current threat of a ‘tripledemic’ that looms over the Northern hemisphere, including many parts of Europe.

Grant to develop automated, rapid point-of-need diagnostic to provide a sustainable and resilient revolution in detection and diagnosis of Porcine Respiratory Disease Complex (PRDC). Working in collaboration with Imperial College, farmers and industry experts to help address the global issue of rising antibiotic resistance.